Ascendis Pharma A (ASND) Prepaid Assets (2012 - 2026)
Ascendis Pharma A (ASND) posted Prepaid Assets of $45.2 million for Q1 2026, up 15.06% sequentially from $39.2 million in Q4 2025, and up 27.49% YoY from $35.4 million in Q1 2025.
Analysis
Ascendis Pharma A (ASND) Prepaid Assets (2012 - 2026) Analysis & Trends
Ascendis Pharma A has reported Prepaid Assets for 15 years, with the latest figure at $45.2 million in Q1 2026.
- Quarterly Prepaid Assets rose 27.49% year-over-year to $45.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.2 million (up 27.49% YoY) and the FY2025 annual result came in at $39.2 million, up 29.92% from the prior year.
- Prepaid Assets grew to $45.2 million in Q1 2026 per ASND's latest filing, from $39.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $46.8 million in Q2 2023 and troughed at $30.2 million in Q4 2024.
- A 5-year average of $38.4 million and a median of $38.8 million in 2025 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets surged 70.0% in 2022, then fell 27.22% in 2024.
- Over 5 years, Prepaid Assets stood at $32.4 million in 2022, then climbed by 28.27% to $41.5 million in 2023, then retreated by 27.22% to $30.2 million in 2024, then grew by 29.92% to $39.2 million in 2025, then grew by 15.06% to $45.2 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $45.2 million, $39.2 million, and $34.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Ascendis Pharma A | 16.39 Bn | 15.45 Bn | 362.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 50.53 Mn |
| Mar 31, 2026 | 45.16 Mn |
| Dec 31, 2025 | 39.25 Mn |
| Sep 30, 2025 | 34.39 Mn |
| Jun 30, 2025 | 38.84 Mn |
| Mar 31, 2025 | 35.42 Mn |
| Dec 31, 2024 | 30.21 Mn |
| Sep 30, 2024 | 35.63 Mn |
| Jun 30, 2024 | 39.57 Mn |
| Mar 31, 2024 | 46.17 Mn |
| Dec 31, 2023 | 41.51 Mn |
| Sep 30, 2023 | 41.72 Mn |
| Jun 30, 2023 | 46.78 Mn |
| Mar 31, 2023 | 41.53 Mn |
| Dec 31, 2022 | 32.36 Mn |
| Sep 30, 2022 | 34.85 Mn |
| Jun 30, 2022 | 37.42 Mn |
| Mar 31, 2022 | 31.42 Mn |
| Dec 31, 2021 | 28.86 Mn |
| Sep 30, 2021 | 26.23 Mn |